The large share of this segment can be attributed to the growing adoption of Ozempic (semaglutide), The diabetes segment dominated the overall GLP-1 agonists market in 2024
Results vary from person to person, but studies show most patients lose around 15% of their starting body weight over 24 weeks, roughly 30 pounds for a 200-pound person
Consult Your Healthcare Provider Before starting Ozempic, consult with your healthcare provider to ensure it is safe and appropriate for your condition
While it has been successful for many patients, its important to be aware of the possible side effects, such as nausea, diarrhea, stomach pain, fatigue, changes to the face, rebound weight gain, and low blood sugar levels
Injectable semaglutide formulations (Ozempic, Wegovy) do not have these timing restrictions
BSO was purchased from Cayman Chemical (Ann Arbor, MI, USA)